Canaccord Genuity Group assumed coverage on shares of CeriBell (NASDAQ:CBLL – Free Report) in a research report sent to investors on Tuesday, Marketbeat Ratings reports. The brokerage issued a buy rating and a $30.00 target price on the stock.
CBLL has been the topic of several other reports. William Blair assumed coverage on shares of CeriBell in a research note on Tuesday. They set an “outperform” rating on the stock. TD Cowen started coverage on shares of CeriBell in a research report on Tuesday. They set a “buy” rating and a $31.00 target price on the stock. Finally, JPMorgan Chase & Co. assumed coverage on CeriBell in a report on Tuesday. They issued an “overweight” rating and a $32.00 price target for the company. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $31.00.
View Our Latest Stock Analysis on CBLL
CeriBell Stock Up 4.2 %
CeriBell Company Profile
We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.
Featured Stories
- Five stocks we like better than CeriBell
- What Are the U.K. Market Holidays? How to Invest and Trade
- Gilead’s Stock Surge: What’s Fueling the Momentum?
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- Breakout Alert: Qualcomm Just Hit The Rally Button
- How to Capture the Benefits of Dividend Increases
- Mercado Libre Shares Go on Sale: Is Now the Time to Buy?
Receive News & Ratings for CeriBell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CeriBell and related companies with MarketBeat.com's FREE daily email newsletter.
